Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus.

× No keyword cloud information.

12 in total

1. Precise standardization of reagents for complement fixation.

Authors: J F KENT; E H FIFE
Journal: Am J Trop Med Hyg Date: 1963-01 Impact factor: 2.345

2. Antinuclear factors and chronic articular inflammation.

Authors: N J Zvaifler; M M Martinez
Journal: Clin Exp Immunol Date: 1971-02 Impact factor: 4.330

3. Immunologic factors and clinical activity in systemic lupus erythematosus.

Authors: P H Schur; J Sandson
Journal: N Engl J Med Date: 1968-03-07 Impact factor: 91.245

4. Iodine-131 labeling of purified microbial antigens by microdiffusion.

Authors: J Gruber; G G Wright
Journal: Proc Soc Exp Biol Med Date: 1967-10

5. Breakdown products of C 3 in human synovial fluids.

Authors: N J Zvaifler
Journal: J Clin Invest Date: 1969-08 Impact factor: 14.808

6. Complement metabolism in man: hypercatabolism of the fourth (C4) and third (C3) components in patients with renal allograft rejection and hereditary, angioedema (HAE).

Authors: C B Carpenter; S Ruddy; I H Shehadeh; H J Müller-Eberhard; J P Merrill; K F Austen
Journal: J Clin Invest Date: 1969-08 Impact factor: 14.808

7. Antibodies to polynucleotides: distribution in human serums.

Authors: D Koffler; R I Carr; V Agnello; T Fiezi; H G Kunkel
Journal: Science Date: 1969-12-26 Impact factor: 47.728

8. In vivo metabolism of complement. I. Metabolism of the third component (C'3) in acquired hemolytic anemia.

Authors: L D Petz; D J Fink; E A Letsky; H H Fudenberg; J Müller-Eberhard
Journal: J Clin Invest Date: 1969-11 Impact factor: 14.808

9. Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients.

Authors: C A Alper; F S Rosen
Journal: J Clin Invest Date: 1967-12 Impact factor: 14.808

10. Complement-derived leukotactic factors in inflammatory synovial fluids of humans.

Authors: P A Ward; N J Zvaifler
Journal: J Clin Invest Date: 1971-03 Impact factor: 14.808

20 in total

Review 1. Pleuropulmonary manifestations of systemic lupus erythematosus.

Authors: M P Keane; J P Lynch
Journal: Thorax Date: 2000-02 Impact factor: 9.139

Review 2. Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?

Authors: M Peakman; G Senaldi; D Vergani
Journal: J Clin Pathol Date: 1989-10 Impact factor: 3.411

3. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors: L H Perrin; P H Lambert; P A Miescher
Journal: J Clin Invest Date: 1975-07 Impact factor: 14.808

Review 4. Complement activation and complement receptors in systemic lupus erythematosus.

Authors: J P Atkinson
Journal: Springer Semin Immunopathol Date: 1986

5. Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation.

Authors: J G Sissons; J Liebowitch; N Amos; D K Peters
Journal: J Clin Invest Date: 1977-04 Impact factor: 14.808

6. Complement metabolism in rheumatoid arthritis. I. Longitudinal studies.

Authors: J M Versey; J R Hobbs; P J Holt
Journal: Ann Rheum Dis Date: 1973-11 Impact factor: 19.103

7. Significance of low molecular weight C1q in systemic lupus erythematosus.

Authors: R Hoekzema; A J Swaak; M C Brouwer; A van Rooijen; E J Nieuwenhuys; C E Hack
Journal: Ann Rheum Dis Date: 1990-09 Impact factor: 19.103

8. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.

Authors: J A Charlesworth; D G Williams; E Sherington; P J Lachmann; D K Peters
Journal: J Clin Invest Date: 1974-06 Impact factor: 14.808

9. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors: K Whaley; P H Schur; S Ruddy
Journal: J Clin Invest Date: 1976-06 Impact factor: 14.808

10. Determination of the half-life of C3 in patients and its relation to the presence of C3-breakdown products and/or circulating immune complexes.

Authors: A J Swaak; A Hannema; C Vogelaar; F A Boom; L van Es; R van Aalst; L W Statius van Eps
Journal: Rheumatol Int Date: 1982 Impact factor: 2.631